跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-APIXABAN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-APIXABAN
Authorized
STANDARD
NAT-APIXABAN
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d94baf7e40ad0115
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
d94baf7e40ad0115
Drug Approval Canada Name
NAT-APIXABAN
Product Name
NAT-APIXABAN
Status
Marketed
Status Date
2022-09-21
Original Market Date
2022-09-21
Din
02492814
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
20:12.04.14
Atc Original
B01AF02 APIXABAN
Atc Name
b 01 af 02
Aig Number
0153051001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
APIXABAN
2.5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d94baf7e40ad0115
Type
Standard
Back to Health Canada Approvals